Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511411-25-00

Acronym

MGT-RPGR-022

Enrollment

Registered

2024-06-21

Start date

2022-08-25

Completion date

Unknown

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene

Brief summary

1. Adverse events 2. Laboratory assessments 3. Change from baseline in best corrected visual acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart letter score in monocular assessment 4. Change from baseline in low luminance visual acuity (LLVA) by ETDRS chart letter score in monocular assessment

Interventions

DRUGOMEPRAZOLE

DRUGVANCOMYCIN

DRUGCEFUROXIME

DRUGJNJ-74765340

DRUGCEFAZOLIN

DRUGTRIAMCINOLONE

DRUGBETAMETHASONE

DRUGDEXAMETHASONE

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
1. Adverse events 2. Laboratory assessments 3. Change from baseline in best corrected visual acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart letter score in monocular assessment 4. Change from baseline in low luminance visual acuity (LLVA) by ETDRS chart letter score in monocular assessment	—

Countries

Belgium, Denmark, France, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026